Added with PD-1 and Tim-3 blockades, BTLA blockade enhanced the expansion, proliferation and cytokine production of NY-ESO-1-specific CD8+ T cells. Collectively, our findings indicate that targeting BTLA along with the PD-1 and Tim-3 pathways is critical to reverse an important mechanism of immune escape in patients with advanced melanoma.
Second, a highly dysfunctional subset of TA-specific T cells present at the periphery or at tumor sites, co-upregulates PD-1 and T cell immunoglobulin and mucin-domaincontaining molecule 3 (Tim-3) expression (5, 6 ). PD-1 and Tim-3 pathway blockades act in synergy to enhance TA-specific CD8+ T cell numbers and functions in patients with advanced melanoma and induce tumor regression in animals (5, 6).
Whether distinct TA-specific CD8+ T cell subsets exhibiting variable levels of dysfunction and expressing different sets of inhibitory molecules exist has not been determined yet. Such information may provide novel therapeutic targets to reverse tumorinduced T cell dysfunction in patients with advanced cancers. To address this question, 4 cells, NK cells and APCs (7-9). BTLA is an inhibitory receptor involved in negative regulation of T cell function. BTLA deficient mice exhibit severe experimental autoimmune encephalomyelitis, prolonged airway allergic inflammation and higher rejection of minor mismatched allografts (8, 10, 11) . BTLA inhibits T cell proliferation and cytokine production in vitro and mediates the negative regulation of CD8+ T cell homeostasis and memory cell generation in vivo (12) . In addition, BTLA plays a critical role in the induction of peripheral T cell tolerance in vivo (13) . BTLA binds to herpes virus entry mediator (HVEM), which is expressed by a wide range of cells including T cells, B cells, NKs, monocytes and dendritic cells (9) . In addition, BTLA is also expressed by melanoma cells (14) . In cancer immunology, BTLA expression has been observed on MART-1-specific CD8+ T cells isolated from PBMCs of melanoma patients and contributed to limiting T cell expansion and IFN-γ production upon cross-linking with HVEM expressed by melanoma cells (14) . In the present study, we show that BTLA expression is upregulated on spontaneous NY-ESO-1-specific CD8+ T cells that are Author Manuscript Published OnlineFirst on December 28, 2011; DOI: 10.1158/0008-5472. CAN-11-2637 6 were collected during flow cytometric analysis on a FACSAria machine (BD Biosciences) and analyzed using Flowjo software (Tree Star).
Intracellular cytokine staining assay. For ex vivo cytokine production assays, two million five hundred thousand purified CD8+ T cells were incubated for 6 hours in 10% human serum DMEM-Iscove medium with the same number of non-CD3 autologous cells pulsed with HLA-A2-restricted peptides NY-ESO-1 157-165 or HIVpol 476-484 (10 µg/ml). For in vitro stimulation (IVS) assays, five million PBMCs were incubated for six days in culture medium containing 50 IU/ml rhIL-2 (PeproTech) with peptide NY-ESO-1 157-165 or peptide HIVpol 476-484 (10 µg/ml) in the presence of 10 µg/ml anti-BTLA (clone 8.2; gift from Dr. Daniel Olive) and/or anti-PD-1 (clone EH12.2H7; Biolegend) and/or anti-Tim-3 (clone 2E2; gift from Dr. Vijay Kuchroo) blocking mAbs or isotype control antibodies. On day 6, cells were restimulated for 6 hours with peptide NY-ESO-1 157-165 or HIVpol 476-484 as control (10 µg/ml). After one hour of incubation, Brefeldin A (Sigma-Aldrich) was added to the culture medium (10 µg/ml).
7
HIVpol 476-484 (10 µg/ml), in the presence of 10 µg/ml anti-BTLA and/or anti-PD-1 and/or anti-Tim-3 blocking mAbs or isotype control antibodies. On day 6, cells were stained with APC-labeled HLA-A2/NY-ESO-1 157-165 tetramers, CD14-ECD, CD19-ECD, CD56-biotin, streptavidin-ECD, CD8-PE-Cy7 and CD4-PerCp-Cy5.5 (Biolegend) conjugated antibodies and reagents. Two million events were collected during flow cytometric analysis.
Statistics. Statistical hypotheses were tested with the Wilcoxon signed rank test (for paired results from the same patient) using SAS v. 9.1 (Cary, NC NY-ESO-1-specific CD8+ T cells (mean 60.4% ± SD 17%) were significantly higher than those of Flu-specific (12.2% ± 10%), CMV-specific (25.2% ± 29.3%), EBV-specific CD8+ T cells (14.8% ± 12%) and total CD8+ T cells (33.8% ± 17.3%) (Fig. 1A and Supplemental Fig. 1 ). As previously shown, BTLA expression was upregulated on MART-1-specific CD8+ T cells (14) . Similar observations were made in terms of mean fluorescence intensity (MFI) (Fig. 1A, right panel) . In line with one previous report (14) , Author Manuscript Published OnlineFirst on December 28, 2011; DOI: 10.1158/0008-5472. CAN-11-2637 which represent the main subsets of NY-ESO-1-specific CD8+ T cells (Fig. 1C) . blockade acts in combination with PD-1 and Tim-3 blockades to further increase the frequencies of proliferating and total NY-ESO-1-specific CD8+ T cells. 
Discussion
In this study, we report a novel subset of dysfunctional TA-specific CD8+ T cells in patients with advanced melanoma. We show that NY-ESO-1-specific 
specific CD8+ T cells. The P values were calculated using the Wilcoxon signed rank test.
Data shown are representative of two independent experiments performed in duplicate. 
